Odyssey Therapeutics Secures $25M Private Placement Concurrent with IPO
ODTX is trading near its 52-week low of $16.405 (6.4% above the low).
Summary
Odyssey Therapeutics completed a $25 million private placement with TPG at its IPO price, bolstering its capital position as it transitions to a public company.
Key Events · Financing and Capital Events · ODTX
-
Private Placement Completed
Odyssey Therapeutics sold 1,388,889 shares of common stock to TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder, for a total of $25,000,002.
-
Pricing at IPO Level
The shares were sold at $18.00 per share, matching the initial public offering price and representing a premium to the current market price of $17.45.
-
Concurrent with IPO
The private placement closed concurrently with the company's initial public offering, providing additional capital as the company went public.
-
Corporate Governance Established
The company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, effective May 11, 2026, in connection with its IPO.
Analysis · ODTX · Life Sciences
This filing details a significant $25 million private placement of common stock to an affiliate of an existing institutional stockholder, TPG, at the initial public offering price of $18.00 per share. This transaction closed concurrently with the company's IPO, providing additional capital and demonstrating strong institutional support for the newly public entity. The private placement price is also at a premium to the current market price of $17.45. The filing also includes standard amendments to the company's corporate charter and bylaws, establishing the governance framework for a public company.
At the time of this filing, ODTX was trading at $17.45 on NASDAQ in the Life Sciences sector. The 52-week trading range was $16.41 to $17.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.